Matches in SemOpenAlex for { <https://semopenalex.org/work/W2753159186> ?p ?o ?g. }
- W2753159186 endingPage "953" @default.
- W2753159186 startingPage "947" @default.
- W2753159186 abstract "Sunitinib is one of the first-line standard treatments for metastatic clear cell renal cell carcinoma (ccRCC) with a median time to progression shorter than 1 year. The objective is to discover predictive markers of response to adapt the treatment at diagnosis.Prospective phase 2 multi-centre trials were conducted in ccRCC patients initiating sunitinib (54 patients) or bevacizumab (45 patients) in the first-line metastatic setting (SUVEGIL and TORAVA trials). The plasmatic level of CXCL7 at baseline was correlated with progression-free survival (PFS).The cut-off value of CXCL7 for PFS was 250 ng ml-1. Patients with CXCL7 plasmatic levels above the cut-off at baseline (250 ng ml-1) had a significantly longer PFS (hazard ratio 0.323 (95% confidence interval 0.147-0.707), P=0.001). These results were confirmed in a retrospective validation cohort. The levels of CXCL7 did not influence PFS of the bevacizumab-treated patients.CXCL7 may be considered as a predictive marker of sunitinib efficacy for ccRCC patients." @default.
- W2753159186 created "2017-09-15" @default.
- W2753159186 creator A5001228294 @default.
- W2753159186 creator A5004989566 @default.
- W2753159186 creator A5017594953 @default.
- W2753159186 creator A5018910230 @default.
- W2753159186 creator A5020353650 @default.
- W2753159186 creator A5020580918 @default.
- W2753159186 creator A5023675047 @default.
- W2753159186 creator A5023915491 @default.
- W2753159186 creator A5034528977 @default.
- W2753159186 creator A5034773695 @default.
- W2753159186 creator A5037025946 @default.
- W2753159186 creator A5039959145 @default.
- W2753159186 creator A5040053100 @default.
- W2753159186 creator A5043550688 @default.
- W2753159186 creator A5045396112 @default.
- W2753159186 creator A5048478589 @default.
- W2753159186 creator A5049425103 @default.
- W2753159186 creator A5049598468 @default.
- W2753159186 creator A5049672639 @default.
- W2753159186 creator A5055022076 @default.
- W2753159186 creator A5059278546 @default.
- W2753159186 creator A5066227680 @default.
- W2753159186 creator A5082215736 @default.
- W2753159186 creator A5083085617 @default.
- W2753159186 creator A5087194857 @default.
- W2753159186 creator A5090050048 @default.
- W2753159186 date "2017-08-29" @default.
- W2753159186 modified "2023-10-17" @default.
- W2753159186 title "CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas" @default.
- W2753159186 cites W1564728191 @default.
- W2753159186 cites W1939417476 @default.
- W2753159186 cites W1968657935 @default.
- W2753159186 cites W1982147571 @default.
- W2753159186 cites W2024586523 @default.
- W2753159186 cites W2026883180 @default.
- W2753159186 cites W2032878609 @default.
- W2753159186 cites W2081187280 @default.
- W2753159186 cites W2099088585 @default.
- W2753159186 cites W2115342244 @default.
- W2753159186 cites W2115966993 @default.
- W2753159186 cites W2118677643 @default.
- W2753159186 cites W2134793155 @default.
- W2753159186 cites W2138129102 @default.
- W2753159186 cites W2143813821 @default.
- W2753159186 cites W2149163652 @default.
- W2753159186 cites W2149456801 @default.
- W2753159186 cites W2150575159 @default.
- W2753159186 cites W2160476851 @default.
- W2753159186 cites W2160724351 @default.
- W2753159186 cites W2222086386 @default.
- W2753159186 cites W2237254160 @default.
- W2753159186 cites W2579645887 @default.
- W2753159186 cites W36309341 @default.
- W2753159186 doi "https://doi.org/10.1038/bjc.2017.276" @default.
- W2753159186 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5625677" @default.
- W2753159186 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28850564" @default.
- W2753159186 hasPublicationYear "2017" @default.
- W2753159186 type Work @default.
- W2753159186 sameAs 2753159186 @default.
- W2753159186 citedByCount "20" @default.
- W2753159186 countsByYear W27531591862018 @default.
- W2753159186 countsByYear W27531591862019 @default.
- W2753159186 countsByYear W27531591862020 @default.
- W2753159186 countsByYear W27531591862021 @default.
- W2753159186 countsByYear W27531591862022 @default.
- W2753159186 countsByYear W27531591862023 @default.
- W2753159186 crossrefType "journal-article" @default.
- W2753159186 hasAuthorship W2753159186A5001228294 @default.
- W2753159186 hasAuthorship W2753159186A5004989566 @default.
- W2753159186 hasAuthorship W2753159186A5017594953 @default.
- W2753159186 hasAuthorship W2753159186A5018910230 @default.
- W2753159186 hasAuthorship W2753159186A5020353650 @default.
- W2753159186 hasAuthorship W2753159186A5020580918 @default.
- W2753159186 hasAuthorship W2753159186A5023675047 @default.
- W2753159186 hasAuthorship W2753159186A5023915491 @default.
- W2753159186 hasAuthorship W2753159186A5034528977 @default.
- W2753159186 hasAuthorship W2753159186A5034773695 @default.
- W2753159186 hasAuthorship W2753159186A5037025946 @default.
- W2753159186 hasAuthorship W2753159186A5039959145 @default.
- W2753159186 hasAuthorship W2753159186A5040053100 @default.
- W2753159186 hasAuthorship W2753159186A5043550688 @default.
- W2753159186 hasAuthorship W2753159186A5045396112 @default.
- W2753159186 hasAuthorship W2753159186A5048478589 @default.
- W2753159186 hasAuthorship W2753159186A5049425103 @default.
- W2753159186 hasAuthorship W2753159186A5049598468 @default.
- W2753159186 hasAuthorship W2753159186A5049672639 @default.
- W2753159186 hasAuthorship W2753159186A5055022076 @default.
- W2753159186 hasAuthorship W2753159186A5059278546 @default.
- W2753159186 hasAuthorship W2753159186A5066227680 @default.
- W2753159186 hasAuthorship W2753159186A5082215736 @default.
- W2753159186 hasAuthorship W2753159186A5083085617 @default.
- W2753159186 hasAuthorship W2753159186A5087194857 @default.
- W2753159186 hasAuthorship W2753159186A5090050048 @default.
- W2753159186 hasBestOaLocation W27531591861 @default.
- W2753159186 hasConcept C121608353 @default.
- W2753159186 hasConcept C126322002 @default.